Abstract:Leukopenia or pancytopenia as a result of bone marrow dysfunction are manifestations of various diseases or complications of therapeutic regimens. The spectrum of diseases associated with leukopenia is wide and includes congenital as well as acquired neutropenias secondary to conditions such as myelodysplastic syndromes, AIDS, malignant tumors with or without chemotherapy-enhanced neutropenia, bone marrow transplantation or therapeutic or accidental radiation. The morbidity and mortality of infectious diseases is greatly enhanced during neutropenic phases. Over the last few years attempts have been made to shorten the duration and lessen the severity of neutropenia in patients with the above conditions by administration of Granulocyte Macrophage Colony Stimulating Factor (G-CSF). Both cytokines were successfully tested in phase I and II trials. Treatment with GM-CSF or G-CSF results in a dose-dependent increase of the neutrophil count. GM-CSF also increases the number of eosinophils and monocytes in peripheral blood. The effect of both cytokines on the neutrophil count is transient as long as the underlying disease persists. This prompted the institution of maintenance therapy, which has been successfully used with either cytokine. Long-term treatment is usually well tolerated and results in a reduction in the frequency of infections as well as in the duration of antibiotic treatments. Side effects of GM-CSF or G-CSF are usually mild and include fever, myalgia, bone pain, and erythema. A number of patients developed dyspnea, hypotension, sweating, flushing and erythema after the first dose of GM-CSF in each treatment cycle. This first-dose reaction occurs more frequently after intravenous than reactions were reported with G-CSF. Some patients with myelodysplastic syndrome progressed to acute myeloic leukemia during or after treatment with GM-CSF or G-CSF. Most of these patients presented with an increased fraction of blasts in the bone marrow, which preceded the treatment with the colony stimulating factors. Since GM-CSF and possibly G-CSF may increase the risk of developing acute leukemia in patients with myelodysplastic syndrome, it appears prudent to limit the use of these cytokines in patients with this disease. The subcutaneous route of administration appears to be preferable to intravenous administration, since the incidence and severity of side effects are reduced. While many questions concerning dosage, long-term therapy and combination therapy still remain unanswered, the information presented in this review concerning the clinical use of these cytokines warrants an optimistic outlook.

Effect of granulocyte colony stimulating factor in immunomodulation and role in intestinal immune homeostasis

[Effect of Granulocyte Colony-Stimulating Factor on Immunological Regulation and Its Application in Allogenic Hematopoietic Stem Cell Transplantation].

Can 29kda Rhgm-Csf Expressed by Silkworm Pupae Bioreactor Bring into Effect As Active Cytokine Through Orally Administration?

Use of Granulocyte Colony-Stimulating Factor in Field of Hematology: Current Status and Prospect in China

GCSF Deficiency Attenuates Nonalcoholic Fatty Liver Disease Through Regulating GCSFR-SOCS3-JAK-STAT3 Pathway and Immune Cells Infiltration.

Granulocyte colony-stimulating factor directly acts on mouse lymphoid-biased but not myeloid-biased hematopoietic stem cells

Effect of Recombinant Human Granulocyte Colony-Stimulating Factor on T-Lymphocyte Function and the Mechanism of This Effect

Granulocyte-macrophage colony-stimulating factor negatively regulates early IL-10-mediated responses

GM-CSF in inflammation

Effects of Granulocyte Colony-Stimulating Factor on Proliferation and Apoptosis of B Cells in Bone Marrow of Healthy Donors

Cell biology and clinical promise of G-CSF: immunomodulation and neuroprotection.

The Effect of Granulocyte Colony-Stimulating Factor on Immune-Modulatory Cytokines in the Bone Marrow Microenvironment and Mesenchymal Stem Cells of Healthy Donors

Old drug, new use: Recent advances for G-CSF

The Progress of Granulocyte-Macrophage Colony-Stimulating Factor on the Mechanism of Acute Lung Injury

GM-CSF: A Double-Edged Sword in Cancer Immunotherapy

Promoting effect of granulocyte-macrophage colony stimulating factor on liver metastasis of colon cancer and its underlying mechanisms

In Vivo Induction of T-cell Hyporesponsiveness and Alteration of Immunological Cells of Bone Marrow Grafts Using Granulocyte Colony-Stimulating Factor.

Directs effects of granulocyte-macrophage colony stimulating factor (GM-CSF) on adaptive immunogenesis

Granulocyte-macrophage colony-stimulating factor: Conductor of the wound healing orchestra?

[GM-CSF and G-CSF: cytokines in clinical application]

Transplantation Of Granulocytic Myeloid-Derived Suppressor Cells (G-Mdscs) Could Reduce Colitis In Experimental Murine Models